Status:
COMPLETED
Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Escherichia Coli Infections
Klebsiella Infections
Eligibility:
All Genders
18+ years
Brief Summary
To determine whether the restriction of 3rd generation cephalosporins and carbapenems contribute to the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in...
Eligibility Criteria
Inclusion
- All patients admitted to or transferred to the MICU.
- Patients 18 years of age or older.
- Provide written informed consent.
Exclusion
- Patients known to be infected or colonized by VRE or ESBL-producing E.coli, K.pneumoniae.
- Patients who have hypersensitivity to penicillin.
- Any underlying conditions or diseases that will be ultimately fatal within 48 hours.
- Any concurrent condition or medication which would interfere with absorption or metabolism of study drugs.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
480 Patients enrolled
Trial Details
Trial ID
NCT00167986
Start Date
January 1 2005
Last Update
March 15 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gyunggi-do, South Korea, 431-070